We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 38

CBD drugs moved to Schedule 5; no promises for cannabis
  • Thompson Coburn LLP
  • USA
  • October 1 2018

The DEA has moved cannabidiol (CBD) drugs (prescription products) with a THC content below .01 to a Schedule 5 (V) drug, provided the drug has been


Connected medical device vulnerabilities continue to impact manufacturers, health care
  • Thompson Coburn LLP
  • USA
  • March 22 2018

Recently, Thompson Coburn’s Life Sciences Decoded blog described several FDA initiatives to increase the safety and reliability of the emerging


FDA to step up enforcement of homeopathic medicine
  • Thompson Coburn LLP
  • USA
  • January 11 2018

Homeopathic medicine has long occupied a niche in American culture. Since 1988, with the issuance of the Compliance Policy Guide, 400.400


Clinical trials Part I: The upcoming clinical trials reporting rule
  • Thompson Coburn LLP
  • USA
  • October 23 2017

In 2007, Congress passed the “Food and Drug Administration Amendments Act of 2007,” the purpose of which was, in part, to update the FDA’s rules


The FDA's new Digital Health Plan
  • Thompson Coburn LLP
  • USA
  • August 22 2017

This latest blog posting focused on only what appears to be a piece of the initiative, the Digital Health Innovation Plan. According to statements by


FDA’s Health Software PreCert Program to fast-track innovation
  • Thompson Coburn LLP
  • USA
  • August 11 2017

Digital information has taken over our day-to-day lives, and the federal Food and Drug Administration (FDA) continues to recognize that this includes


Privacy and the Internet of Medical Things: What’s a curmudgeon to do?
  • Thompson Coburn LLP
  • USA
  • April 12 2017

One of the authors of this piece uses a medical device that is wirelessly networked to the device’s vendor. The author recently received a text


DEA awards Schedule II classification to synthetic THC drug
  • Thompson Coburn LLP
  • USA
  • April 4 2017

On March 23, 2017, the DEA announced it has scheduled the newly approved synthetic THC-containing drug, Syndros, as a Class II substance. This


Food industry sees one of first whistleblower suits under FSMA
  • Thompson Coburn LLP
  • USA
  • February 10 2017

As part of the massive overhaul of food safety regulations under the Food Safety Modernization Act, Life Sciences Decoded reported in August on new


Food contact goods and the FSVP: Deciphering the FDA’s stance
  • Thompson Coburn LLP
  • USA
  • February 10 2017

The last 18 months have seen a flurry of regulatory activity as the FDA has finalized and begun enforcing a number of new regulations based on the